GlobalData is the parent company of Clinical Trials Arena. "Ocugen sets sights on Phase III after GA gene therapy win" was ...

Companies across the globe are diligently working toward developing novel Dry Age Macular Degeneration treatment therapies ...

Scientists at USC are launching a new trial to test a tiny stem cell implant that could restore vision in people with ...

An editorial published today in The New England Journal of Medicine (NEJM) writes that Science Corporation's PRIMA implant is the first treatment in clinical trials to successfully restore functional ...

In advanced dry disease, a key problem is failure of retinal pigment epithelium, often shortened to RPE. These cells help ...

Ocugen has reported preliminary phase 2 data on its eye disease gene therapy, providing more evidence that the candidate may ...

Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. controlThere are no OCU410-related serious ...

The FDA granted fast track designation for CTx001, an investigational gene therapy candidate for geographic atrophy secondary ...

Ask a clinical question and tap into Healio AI's knowledge base. Assessment of visual function by testing for visual acuity, dark adaptation, contrast sensitivity and evaluation of retinal sensitivity ...

Ollin Biosciences has announced positive topline results from its randomized, head-to-head Phase 1b JADE clinical study ...